银屑病患者接受生物制剂治疗时乙肝和丙肝病毒再激活风险:回顾性队列研究与系统综述
该研究评估了银屑病患者接受生物制剂治疗时乙肝或丙肝病毒再激活的风险。回顾性队列纳入30例血清学阳性患者,随访期间无肝炎或病毒再激活。系统综述纳入49项研究共312例患者,显示核心抗体阳性者和HCV感染者年再激活率分别为0.32%和2.42%,而慢性HBV感染者为13.92%。结论认为低风险患者再激活风险极小,但慢性HBV感染者风险较高,需抗病毒预防。
要点
- 慢性HBV感染者生物制剂治疗再激活风险较高,年再激活率13.92%。
- 核心抗体阳性或HCV感染者再激活风险较低,年再激活率分别为0.32%和2.42%。
- 慢性HBV感染者需考虑抗病毒预防以降低再激活风险。
核心结论
- 生物制剂对无肝炎血清学阳性的低风险患者(HCV或HBV核心抗体阳性)病毒再激活风险极小,但对慢性HBV感染者风险较高,强调抗病毒预防的必要性。
研究设计与样本
- 回顾性队列研究纳入30例接受生物制剂治疗且HBV或HCV血清学阳性的银屑病患者,并进行系统综述纳入49项研究共312例患者。
主要发现
- 队列随访(平均4.85±3.1年)期间无患者发生肝炎或病毒再激活。
- 系统综述中,核心抗体阳性患者病毒再激活2/175例(年率0.32%),HCV感染患者3/97例(年率2.42%),慢性HBV感染患者8/40例(年率13.92%)。
- 8例再激活的慢性HBV感染者中3例接受了抗病毒预防。
关键数值与推荐
- 核心抗体阳性患者年再激活率0.32%(2/175),HCV感染患者年再激活率2.42%(3/97),慢性HBV感染患者年再激活率13.92%(8/40)。
临床怎么用
- 对慢性HBV感染者接受生物制剂治疗时应考虑抗病毒预防,对HCV或HBV核心抗体阳性者风险较低但仍需监测。
局限性
- 系统综述汇总了评估不同生物制剂的异质性研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients with psoriasis on biologic therapies and a history of viral hepatitis carry a risk for reactivation. OBJECTIVE: We evaluated safety of biologic therapies in psoriasis patients seropositive for hepatitis B or C viruses (HBV, HCV). METHODS: A retrospective cohort study design was used. Clinical and laboratory data for 30 patients undergoing biologic therapy who were seropositive for HBV or HCV were evaluated. Next, a systematic review was performed. Primary outcomes were hepatitis and viral reactivation during therapy. Treatment duration and antiviral prophylaxis were also recorded. RESULTS: Serology indicated HCV infection in 4 patients, past HBV infection in 17 patients, isolated core antibody in 8 patients, and chronic HBV infection in 1 patient. During follow-up (mean 4.85 ± 3.1 years), no patients experienced hepatitis or viral reactivation. The systematic review of the literature included 49 studies comprising 312 patients followed for a mean of 30.9 months. Viral reactivation occurred in 2/175 patients who were seropositive for core antibody and 3/97 with HCV infection (yearly rates, 0.32% and 2.42%, respectively) compared with 8/40 patients with chronic HBV infection (yearly rate, 13.92%). Three of these 8 patients with reactivated HBV infection received antiviral prophylaxis. LIMITATIONS: We pooled heterogeneous studies evaluating different biologic therapies. CONCLUSION: Biologic therapies pose minimal risk for viral reactivation in low-risk patients without hepatitis seropositive for HCV or HBV core antibody but are a considerable risk in patients with chronic HBV infection, highlighting the necessity of antiviral prophylaxis.
引用
- Snast I, Atzmony L, Braun M, et al. Risk for hepatitis B and C virus reactivation in patients with psoriasis on biologic therapies: A retrospective cohort study and systematic review of the literature. J Am Acad Dermatol. 2017. PMID: 28495497. doi:10.1016/j.jaad.2017.01.037
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。